Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
Do you rebiopsy grade 1-2 follicular lymphoma if SUV is high by PET?
What are the scenarios in which a rebiopsy is warranted for follicular lymphoma?
Related Questions
Is there an optimal salvage radiation dose for relapsed post-CART disease?
Are there biomarkers or other factors to help predict which patients with MCL are most likely to benefit, or not, from pirtobrutinib following a prior covalent BTKi?
How you treat large B-cell lymphoma with IRF4 rearrangement?
What is your preferred salvage therapy for patients with follicular lymphoma who relapsed within 24 months of completing front-line chemoimmunotherapy and will proceed to high-dose therapy with autologous progenitor cell rescue?
How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
How would you treat an otherwise healthy patient with newly diagnosed Stage IIA unfavorable classical Hodgkin lymphoma who has exceeded lifetime anthracycline dose (for other indications, not treated previously for Hodgkins)?
Following the BRUIN data in mantle cell lymphoma, will you routinely treat with pirtobrutinib following a covalent BTKi?
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?
How would you treat an otherwise healthy patient with newly diagnosed Stage IIA unfavorable classical Hodgkin lymphoma who has exceeded lifetime anthracycline dose (for other indications, not treated previously for Hodgkins)?